Company info
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Description
NewLimit is seeking an scientist with experience in liver biology and metabolism to join our Metabolism team. Our Metabolism team is developing reprogramming medicines to restore youthful function in aged hepatocytes in the context of metabolic disease. In this role, you will develop and perform assays for hepatocyte function, contribute to team decision making, and serve as a subject matter expert within NewLimit to enable our therapeutic development efforts.
As a Scientist on our team, you will:
- Collaborate with our Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test epigenetic reprogramming interventions for aged and diseased hepatocytes
- Develop assays to measure hepatocyte function both ex vivo and in vivo
- Evaluate epigenetic reprogramming payloads using ex vivo and in vivo functional assays to select therapeutic candidates
- Develop methods for in vivo delivery of nucleic acid payloads to hepatocytes in collaboration with our Epigenetic Editing team
- Analyze and interpret experimental data to drive pre-clinical decision making
Requirements
- Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
- Experience with primary liver cell isolation and functional characterization
- Experience working with mouse models of liver dysfunction
- Experience with transgenic manipulation of liver cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)
Nice to have
- History of contributing to a drug development program at the pre-clinical or clinical development stage
- Experience leading the design and execution of pre-clinical studies in mouse models
- Experience with single cell genomics methods
- Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)
What We Do
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
